Cargando…

Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer

BACKGROUND: Poly(ADP-ribose) polymerase (PARP) inhibitors (eg, olaparib) are effective against BRCA-mutated cancers at/near maximum tolerated doses by trapping PARP-1 on damaged chromatin, benefitting only small patient proportions. The benefits of targeting non-DNA repair aspects of PARP with metro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghonim, Mohamed A, Ibba, Salome V, Tarhuni, Abdelmetalab F, Errami, Youssef, Luu, Hanh H, Dean, Matthew J, El-Bahrawy, Ali H, Wyczechowska, Dorota, Benslimane, Ilyes A, Del Valle, Luis, Al-Khami, Amir A, Ochoa, Augusto C, Boulares, A Hamid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839867/ https://www.ncbi.nlm.nih.gov/pubmed/33495297 http://dx.doi.org/10.1136/jitc-2020-001643

Ejemplares similares

Sulfated non-anticoagulant heparin blocks Th2-induced asthma by modulating the IL-4/signal transducer and activator of transcription 6/Janus kinase 1 pathway
por: Ghonim, Mohamed A., et al.
Publicado: (2018)

PARP-1 Is Critical for Recruitment of Dendritic Cells to the Lung in a Mouse Model of Asthma but Dispensable for Their Differentiation and Function
por: Echeverri Tirado, Laura C., et al.
Publicado: (2019)

Promotion of a synthetic degradation of activated STAT6 by PARP-1 inhibition: roles of poly(ADP-ribosyl)ation, calpains and autophagy
por: Wang, Jeffrey, et al.
Publicado: (2022)

PARP is activated in human asthma and its inhibition by olaparib blocks house dust mite-induced disease in mice
por: Ghonim, Mohamed A., et al.
Publicado: (2015)

PARP inhibition by olaparib or gene knockout blocks asthma-like manifestation in mice by modulating CD4(+) T cell function
por: Ghonim, Mohamed A, et al.
Publicado: (2015)

Correction: ApoE deficiency promotes colon inflammation and enhances the inflammatory potential of oxidized-LDL and TNF-α in primary colon epithelial cells
por: El-Bahrawy, Ali H., et al.
Publicado: (2016)

ApoE deficiency promotes colon inflammation and enhances the inflammatory potential of oxidized-LDL and TNF-α in primary colon epithelial cells
por: El-Bahrawy, Ali H., et al.
Publicado: (2016)

Potential of Inducible Nitric Oxide Synthase as a Therapeutic Target for Allergen-Induced Airway Hyperresponsiveness: A Critical Connection to Nitric Oxide Levels and PARP Activity
por: Ibba, Salome' V., et al.
Publicado: (2016)

Poly(ADP-ribose) polymerase as a novel regulator of 17β-estradiol-induced cell growth through a control of the estrogen receptor/IGF-1 receptor/PDZK1 axis
por: Kim, Hogyoung, et al.
Publicado: (2015)

PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations
por: Fabian, Kellsye P, et al.
Publicado: (2020)

Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation
por: Cassetta, Luca, et al.
Publicado: (2020)

Correction: Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1- immunotherapy in colon cancer
Publicado: (2021)

STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer
por: Ding, Liya, et al.
Publicado: (2023)

Independent mechanisms of T cell-suppression by subpopulations of myeloid-derived suppressor cells (MDSC) in tumor-bearing hosts
por: Raber, Patrick L, et al.
Publicado: (2013)

Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib
por: Bocci, G, et al.
Publicado: (2008)

T cells conditioned with MDSC show an increased anti-tumor activity after adoptive T cell based immunotherapy
por: Raber, Patrick L., et al.
Publicado: (2016)

Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma
por: Cham, K K Y, et al.
Publicado: (2010)

Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth
por: Parra, Karla, et al.
Publicado: (2017)

VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide
por: Orlandi, P, et al.
Publicado: (2013)

PARP inhibition and immune modulation: scientific rationale and perspectives for the treatment of gynecologic cancers
por: Lee, Elizabeth K., et al.
Publicado: (2020)

Are PARPs promiscuous?
por: Feijs, Karla L.H., et al.
Publicado: (2022)

Metronomic chemotherapy in patients with advanced neuroendocrine tumors: A single‐center retrospective analysis
por: Arrivi, Giulia, et al.
Publicado: (2022)

Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies
por: Schöffski, Patrick, et al.
Publicado: (2022)

Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules
por: Murray, J, et al.
Publicado: (2014)

Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase
por: Znojek, P, et al.
Publicado: (2014)

A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors
por: Naing, Aung, et al.
Publicado: (2020)

First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors
por: Hamid, Omid, et al.
Publicado: (2022)

Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival
por: Sussman, Tamara A, et al.
Publicado: (2021)

Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors
por: Mamoor, Maha, et al.
Publicado: (2020)

Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity
por: Horn, Lucas A, et al.
Publicado: (2020)

Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models
por: Zhang, Ling, et al.
Publicado: (2020)

MLH1 mediates PARP-dependent cell death in response to the methylating agent N-methyl-N-nitrosourea
por: McDaid, J R, et al.
Publicado: (2009)

Antibody profiling of patients with prostate cancer reveals differences in antibody signatures among disease stages
por: Potluri, Hemanth K, et al.
Publicado: (2020)

Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies
por: Adegoke, Nurudeen A, et al.
Publicado: (2023)

A very long-acting IL-15: implications for the immunotherapy of cancer
por: Hangasky, John A, et al.
Publicado: (2022)

In situ vaccination at a peripheral tumor site augments response against melanoma brain metastases
por: Clark, Paul A, et al.
Publicado: (2020)

Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer
por: Friedman, Claire F, et al.
Publicado: (2020)

Characterization of the treatment-naive immune microenvironment in melanoma with BRAF mutation
por: Wang, Minyu, et al.
Publicado: (2022)

Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma
por: Nghiem, Paul, et al.
Publicado: (2021)

An (89)Zr-HDL PET Tracer Monitors Response to a CSF1R Inhibitor
por: Mason, Christian A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4v7s1icjss2asmf1b236n7jr8u